Jeito Capital Leads €132M Series to Advance Phase 3 Trials for Rare Neuro-Metabolic Disorders
By Daniella Parra Jeito Capital said it is leading a €132 million oversubscribed Series B funding round in Azafaros, a clinical-stage biotech company developing treatments for rare lysosomal storage disorders. Azafaros, founded in 2018 and rooted in Dutch academic research,...